Inhibition of p90RSK activation sensitizes triple-negative breast cancer cells to cisplatin by inhibiting proliferation, migration and EMT
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Cisplatin (Cis-DDP) is one of the most widely used anti-cancer drugs. It is applicable to many types of cancer, including lung, bladder, and breast cancer. However, its use is now limited because of drug resistance. p90 ribosomal S6 kinase (p90RSK) is one of the downstream effectors in the extracellular signalregulated protein kinases 1 and 2 (ERK1/2) pathway and high expression of p90RSK is observed in human breast cancer tissues. Therefore, we investigated the role of p90RSK in the Cis-DDP resistance-related signaling pathway and epithelialmesenchymal transition (EMT) in breast cancer cells. First, we discovered that MDA-MB-231 cells exhibited more Cis-DDP resistance than other breast cancer cells, including MCF-7 and BT549 cells. Cis-DDP increased p90RSK activation, whereas the inactivation of p90RSK using a small interfering RNA (siRNA) or dominant-negative kinase mutant plasmid overexpression significantly reduced Cis-DDP-induced cell proliferation and migration via the inhibition of matrix metallopeptidase (MMP)2 and MMP9 in MDA-MB-231 cells. In addition, p90RSK activation was involved in EMT via the upregulation of mRNA expression, including that of Snail, Twist, ZEB1, N-cadherin, and vimentin. We also investigated NF-B, the upstream regulator of EMT markers, and discovered that Cis-DDP treatment led to NF-B translocation in the nucleus as well as its promoter activity. Our results suggest that targeting p90RSK would be a good strategy to increase Cis-DDP sensitivity in triple-negative breast cancers.
Abstract
Cisplatin (Cis-DDP) is one of the most widely used anti-cancer drugs. It is applicable to many types of cancer, including lung, bladder, and breast cancer. However, its use is now limited because of drug resistance. p90 ribosomal S6 kinase (p90RSK) is one of the downstream effectors in the extracellular signalregulated protein kinases 1 and 2 (ERK1/2) pathway and high expression of p90RSK is observed in human breast cancer tissues. Therefore, we investigated the role of p90RSK in the Cis-DDP resistance-related signaling pathway and epithelialmesenchymal transition (EMT) in breast cancer cells. First, we discovered that MDA-MB-231 cells exhibited more Cis-DDP resistance than other breast cancer cells, including MCF-7 and BT549 cells. Cis-DDP increased p90RSK activation, whereas the inactivation of p90RSK using a small interfering RNA (siRNA) or dominant-negative kinase mutant plasmid overexpression significantly reduced Cis-DDP-induced cell proliferation and migration via the inhibition of matrix metallopeptidase (MMP)2 and MMP9 in MDA-MB-231 cells. In addition, p90RSK activation was involved in EMT via the upregulation of mRNA expression, including that of Snail, Twist, ZEB1, N-cadherin, and vimentin. We also investigated NF-B, the upstream regulator of EMT markers, and discovered that Cis-DDP treatment led to NF-B translocation in the nucleus as well as its promoter activity. Our results suggest that targeting p90RSK would be a good strategy to increase Cis-DDP sensitivity in triple-negative breast cancers.
참고문헌 (25)
- Jung J, "Novel cancer gene variants and gene fusions of triple-negative breast cancers(TNBCs)reveal their molecular diversity conserved in the patient-derived xenograft(PDX)model", Cancer Lett, 428, pp.127~138 (2018)
- 박재인, "BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer", BMB Reports, 51(8), pp.373~377 (2018), 생화학분자생물학회
- Dasari S, "Cisplatin in cancer therapy : molecular mechanisms of action", Eur J Pharmacol, 740, pp.364~378 (2014)
- Verma N, "Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis", Cancer Res, 77, pp.86~99 (2017)
- Qin H, "PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1", 2-MMP2 signaling, 2017, pp.409, 30~41
- 김한별, "Clinical implications of the Hippo-YAP pathway in multiple cancer contexts", BMB Reports, 51(3), pp.119~125 (2018), 생화학분자생물학회
- Ludwik KA, "Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer", Mol Cancer Ther, 15, pp.2598~2608 (2016)
- Lin L, "Role of p90RSK in Kidney and Other Diseases", Int J Mol Sci, 20, pp.E972~ (2019)
- Chen S, "Differential regulation of NHE1 phosphorylation and glucose uptake by inhibitors of the ERK pathway and p90RSK in 3T3-L1 adipocytes", Cell Signal, 21, pp.1984~1993 (2009)
- Ikuta M, "Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands : Implications for the design of RSK1 specific inhibitors", Protein Sci, 16, pp.2626~2635 (2007)
- Tas I, "Physciosporin suppresses the proliferation, motility and tumourigenesis of colorectal cancer cells", Phytomedicine, 56, pp.10~20 (2019)
- Melhuish TA, "Myt1and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression", Biochim Biophys Acta Gene Regul Mech, 1861, pp.983~995 (2018)
- de Cassia Viu Carrara R, "Expression differences of genes in the PI3K", AKT, WNT, Clin Transl Oncol, pp.2018, 20[DOI]
- Lim W, "Inhibitory Effects of Quercetin on Progression of Human Choriocarcinoma Cells Are Mediated Through PI3K", AKT and MAPK Signal Transduction Cascades, 2017, pp.232, 1428~1440
- Zhao T, "Simulated Microgravity Reduces Focal Adhesions and Alters Cytoskeleton and Nuclear Positioning Leading to Enhanced Apoptosis via Suppressing FAK", RhoA-Mediated mTORC1, 2 Pathways, pp.Int J Mol Sci, 2018[DOI]
- Sheng W, "Calreticulin promotes EGF-induced EMT in pancreatic cancer cells via Integrin", EGFR-ERK, Cell Death Dis, pp.2017, 8[DOI]
- Kuwano M, "Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer", Cancer Sci, 110, pp.1536~1543 (2019)
- Moon HG, "Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer", BMC Cancer, 12, pp.585~ (2012)
- Ashaie MA, "Cadherins : The Superfamily Critically Involved in Breast Cancer", Curr Pharm Des, 22, pp.616~638 (2016)
- Wang Y, "Epithelial-mesenchymal transition in breast cancer progression and metastasis", Chin J Cancer, 30, pp.603~611 (2011)
- Hong J, "Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes Twist1 protein and promotes breast cancer cell invasiveness", Cancer Res, 71, pp.3980~3990 (2011)
- Lin S, "Actinomycin V Inhibits Migration and Invasion via Suppressing Snail", Slug-Mediated Epithelial-Mesenchymal Transition Progression in Human Breast Cancer MDA-MB-231 Cells In Vitro, 2019, pp.17, 305~
- Harquail J, "Pax-5 Inhibits NF-kappaB Activity in Breast Cancer Cells Through IKKepsilon and miRNA-155 Effectors", J Mammary Gland Biol Neoplasia, 23, pp.177~187 (2018)
- Heo KS, "Phosphorylation of protein inhibitor of activated STAT1(PIAS1)by MAPK-activated protein kinase-2 inhibits endothelial inflammation via increasing both PIAS1 transrepression and SUMO E3 ligase activity", Arterioscler Thromb Vasc Biol, 33, pp.321~329 (2013)
- Heo KS, "Disturbed flow-activated p90RSK kinase accelerates atherosclerosis by inhibiting SENP2 function", J Clin Invest, 125, pp.1299~1310 (2015)